WO2022256358A1 - Process for preparing medicaments - Google Patents

Process for preparing medicaments Download PDF

Info

Publication number
WO2022256358A1
WO2022256358A1 PCT/US2022/031685 US2022031685W WO2022256358A1 WO 2022256358 A1 WO2022256358 A1 WO 2022256358A1 US 2022031685 W US2022031685 W US 2022031685W WO 2022256358 A1 WO2022256358 A1 WO 2022256358A1
Authority
WO
WIPO (PCT)
Prior art keywords
afford
mol
chloro
nitroso
difluoromethoxy
Prior art date
Application number
PCT/US2022/031685
Other languages
French (fr)
Inventor
Andreas Stumpf
David Lao
Remy Angelaud
Andreas Marx
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Hoffmann-La Roche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc. filed Critical Genentech, Inc.
Publication of WO2022256358A1 publication Critical patent/WO2022256358A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Definitions

  • the present invention relates to a new and improved process for the preparation of synthetic intermediates useful for the synthesis of medicaments including JAK kinases of formula 1.
  • One object of the present invention is an improved process, which efficiently implemented on commercial scale.
  • Janus kinases including JAK1, JAK2, JAK3 and TYK2, are cytoplasmic protein kinases that associate with type I and type II cytokine receptors and regulate cytokine signal transduction. Cytokine pathways mediate a broad range of biological functions, including many aspects of inflammation and immunity.
  • the invention affords (z) a sequential difluoromethylation and Claisen condensation to afford enolate 4 without isolation of the intermediate, (//) one-pot nitrosation of 4 followed by condensation with hydrazine to form nitrosopyrazole 6, and (zzz) subsequent reduction of the nitroso group using sodium borohydride and catalytic copper(I) chloride to produce target compound 7.
  • the optimized process delivered highly pure 7 (99.9 A% by HPLC) in overall 28% yield over 5 steps.
  • the aminopyrazole intermediate 7 can be condensed with pyrazolo[l,5-a]pyrimidine-3- carboxylic acid a]pyrimidine-3-carboxylic acid (II) to afford 2-(4-amino-3-(5-chloro-2- (difluoromethoxy)phenyl)-lH-pyrazol-l-yl)-N,N-dimethylacetamide (III) and N-alkylated with N,N-dimethyl-bromoacetamide to afford I.
  • a or “an” entity refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound.
  • a compound refers to one or more compounds or at least one compound.
  • the terms “a” (or “an”), “one or more”, and “at least one” can be used interchangeably herein.
  • the terms “comprise(s)” and “comprising” are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases “having at least” or “including at least”.
  • the term “comprising” means that the process includes at least the recited steps, but may include additional steps.
  • the term “comprising” means that the compound or composition includes at least the recited features or components, but may also include additional features or components.
  • a bond drawn into ring system indicates that the bond may be attached to any of the suitable ring atoms.
  • optionally substituted means that the optionally substituted moiety may incorporate a hydrogen or a substituent.
  • the term “treating”, “contacting” or “reacting” when referring to a chemical reaction means to add or mix two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • An optionally substituted 2-hydroxyacetophenone refers to a compound which is optionally further substituted with one or two halogens, C 1-3 alkyl, Ci- 3 -alkoxy, Ci- 3 -haloalkoxy moieties.
  • alkyl as used herein alone or in combination with other groups, denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms.
  • lower alkyl denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms.
  • Ci- 6 alkyl refers to an alkyl composed of 1 to 6 carbons.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl, neope
  • haloalkyl denotes an alkyl group as defined above wherein at least one hydrogen atom is substituted by a halogen.
  • Examples are 1-fluorom ethyl, 1 -chi orom ethyl, 1-bromom ethyl, 1- iodom ethyl, difluorom ethyl, trifluoromethyl, tri chi orom ethyl, 1-fluoroethyl, 1-chloroethyl, 2- fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2- trifluoroethyl.
  • alkoxy as used herein means an -O-alkyl group, wherein alkyl is as defined above, such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, t- butyloxy, pentyloxy, hexyloxy, including their isomers.
  • Lower alkoxy as used herein denotes an alkoxy group with a "lower alkyl” group as previously defined.
  • Ci-io alkoxy refers to an-O-alkyl wherein alkyl is Ci-io.
  • haloalkoxy refers to a group -OR where R is haloalkyl as defined herein.
  • haloalkylthio refers to a group -SR where R is haloalkyl as defined herein.
  • halogen or "halo” as used herein means fluorine, chlorine, bromine, or iodine.
  • halo halogen
  • halide halogen
  • Reduction of a nitro group to an amine can be accomplished with a metal reducing agent such as Fe, Sn or Zn, in a reaction inert solvent, e.g. MeOH, EtOH, EtOAc, benzene, toluene, xylene, o-dichlorobenzene, DCM, DCE, THF, dioxane, or mixtures thereof.
  • a metal reducing agent such as Fe, Sn or Zn
  • a reaction inert solvent e.g. MeOH, EtOH, EtOAc, benzene, toluene, xylene, o-dichlorobenzene, DCM, DCE, THF, dioxane, or mixtures thereof.
  • the reducing reagent is Fe, Sn or Zn
  • the reaction is carried out under acidic conditions in the presence of water.
  • the reduction may be carried out by hydrogenation in the presence of a metal catalyst, e.g.
  • nickel catalysts such as Raney nickel, palladium catalysts such as Pd/C, platinum catalysts such as PtCh, or ruthenium catalysts such as RuCh(Ph3P)3 under Eh atmosphere or in the presence of hydrogen sources such as hydrazine or formic acid. If desired, the reaction is carried out under acidic conditions, e.g, in the presence of HC1 or HOAc.
  • Carboxylic acids can be can be activated with agents such as EDC, DCC, benzotriazol-1 - yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), bromo-tris- pyrrolidinophosphonium hexafluorophosphate (PyBrOP), or 2-fluoro-l-methylpyridinium p- toluenesulphonate (Mukaiyama's reagent with or without a base such NMM, TEA or DIPEA in an inert solvent such as dimethylformamide (DMF) or di chi orom ethane at temperatures between 0 °C and 60 °C.
  • agents such as EDC, DCC, benzotriazol-1 - yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), bromo-tris- pyrrolidinophosphonium he
  • a reactor was charged with l-(5-chloro-2-hydroxyphenyl)ethan-l-one (2, 135 kg, 791 mol, 100 mol%), 2-propanol (541 kg), aqueous sodium hydroxide (539 kg, 4043 mol, 511 mol%, 30 wt%), and heated to 49 °C.
  • Dichlorofluoromethane (248 kg, 2410 mol, 305 mol%) was bubbled into the reaction mixture and heated at 49 °C for >20 min until reaction was complete ( ⁇ 0.5 A% HPLC).
  • the mixture was cooled to 20 °C and filtered.
  • the cake was washed with 2-propanol (135 kg), and the combined filtrates charged back into the reactor.
  • the reactor was heated to 27 °C for 15 min, let stand for 40 min without stirring to achieve phase separation and the aqueous phase was drained.
  • the remaining organic phase was concentrated to ⁇ 200 L under reduced pressure at 45 °C, toluene (652 kg) was charged and heated to 27 °C for 40 min.
  • the mixture was filtered and the cake washed with toluene (132 kg).
  • the combined filtrates were recharged into the reactor followed by a rinse with toluene (50 kg).
  • the reactor content was concentrated to -200 L under reduced pressure at 45 °C, toluene (268 kg) was charged and the solution of l-(5- chloro-2-
  • a reactor was charged with ethyl formate (159.0 kg, 2146 mol, 328 mol%), a solution of 1- (5-chloro-2-(difluoromethoxy)phenyl)ethan-l-one (3) in toluene (144.5 kg assay corrected from the precursor step, 655 mol, 100 mol%), toluene (392 kg), ethyl formate (10.0 kg, 135 mol, 21 mol%), and heated to 41 °C.
  • a solution of NaOEt in EtOH 360.0 kg, 952 mol, 145 mol%, 18 wt%) and toluene (16 kg) was charged and heated to 46 °C for 4 h.
  • HPLC analysis showed 2 to be 2.1 A%.
  • the reactor content was concentrated to -1100 L at ⁇ 40 °C under reduced pressure, heptane (578 kg) was added and the mixture was concentrated to -800 L at ⁇ 40 °C under reduced pressure, heptane (346 kg) was added again and the mixture concentrated to -800 L at ⁇ 40 °C. This cycle was repeated 2 more times (using 346 kg of heptane each) followed by a last charge of heptane (340 kg). The reactor contents were then heated to 44 °C for 1 h, and cooled over 3 h to -3 °C, and stirred at this temperature for 2 h.
  • a reactor was charged with formic acid (354 kg), acetonitrile (156 kg), water (44 kg) and cooled to -3 °C.
  • Sodium (Z)-3-(5-chloro-2-(difluoromethoxy)phenyl)-3-oxoprop-l-en-l- olate (4) (67.0 kg assay corrected, 248 mol, 100 mol%) was added in one charge, and a solution of aqueous NaNC (110 kg, 303 mol, 122 mol%, 19 wt%) was dosed into the solution over 1 h, followed by a rinse with water (4 kg), and stirred for 3 h. HPLC analysis showed 4 was undetected.
  • the reactor was heated to 2 °C, aqueous hydrazine monohydrate (102 kg, 326 mol, 131 mol%, 16 wt%) was added over 1 h and stirred for 3 h at 6 °C. HPLC analysis showed 5 to be 1.0 A%.
  • the reactor was charged with toluene (57 kg), followed by water (468 kg) over 1 h, and cooled to - 7 °C for 4 h.
  • a reactor was charged with NaBH4 (92.9 kg, 2455 mol, 1681 mol%), CuCl (1.10 kg, 11 mol, 69 mol%), THF (440 kg) and heated to 26 °C.
  • a solution of 6 (41.6 kg, 146 mol, 100 mol%) in EtOH (360 kg) was added over 15 h, followed by two rinses with EtOH (50 kg, 48 kg), and continued to stir for 24 h.
  • HPLC analysis showed 6 to be 0.5 A%.
  • a solution of HC1 gas in EtOH (653 kg, 4966 mol, 3400 mol%, 6 M) was added over 16 h and stirred at 22 °C for 3 h.
  • Diatomaceous earth (86.2 kg, diatomite) and EtOH (11 kg) was added and stirred for 2 h at 26 °C .
  • the mixture was filtered and the cake washed with five portions of EtOH (256 kg each).
  • the combined filtrate was charged to a reactor and concentrated to -270 L at ⁇ 45 °C under reduced pressure.
  • the reactor was cooled to 26 °C, charged with MeOH (600 kg) and concentrated to -230 L at ⁇ 45 °C under reduced pressure.
  • the reactor was cooled to 26 °C, charged with MeOH (486 kg) and concentrated to -230 L at ⁇ 45 °C under reduced pressure.
  • the reactor was cooled to 26 °C, charged with MeOH (102 kg), title compound seeds and concentrated to -230 L at ⁇ 45 °C under reduced pressure.
  • the reactor was cooled to 26 °C, charged with MTBE (700 kg) and cooled over 4 h to 2 °C and held at this temperature for 8 h.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present application affords an improved preparation of 3-(5-chloro-2-(difluoromethoxy)phenyl)-1H-pyrazol-4-amine hydrochloride qhich was a useful intermediate in the synthesis of JAK inhibitors.

Description

PROCESS FOR PREPARING MEDICAMENTS
FIELD OF THE INVENTION
The present invention relates to a new and improved process for the preparation of synthetic intermediates useful for the synthesis of medicaments including JAK kinases of formula 1. One object of the present invention is an improved process, which efficiently implemented on commercial scale.
BACKGROUND OF THE INVENTION
Janus kinases (JAK), including JAK1, JAK2, JAK3 and TYK2, are cytoplasmic protein kinases that associate with type I and type II cytokine receptors and regulate cytokine signal transduction. Cytokine pathways mediate a broad range of biological functions, including many aspects of inflammation and immunity.
A series of pyrazolo[l,5-a]pyrimidines afforded JAK inhibitors remarkably efficacious for the treatment of asthma and inflammatory diseases (E. Hanan etal, ./. Med. Chem ., 2012 55:10090-10107; M. Zak, etal. WO2015/177326; M. Zak, etal., 2018/215389). Compound I was selected for additional testing which required larger quantities for further clinical evaluation.
Figure imgf000002_0001
BRIEF SUMMARY OF THE INVENTION
The invention affords (z) a sequential difluoromethylation and Claisen condensation to afford enolate 4 without isolation of the intermediate, (//) one-pot nitrosation of 4 followed by condensation with hydrazine to form nitrosopyrazole 6, and (zzz) subsequent reduction of the nitroso group using sodium borohydride and catalytic copper(I) chloride to produce target compound 7. The optimized process delivered highly pure 7 (99.9 A% by HPLC) in overall 28% yield over 5 steps. (SCHEME 1) SCHEME 1
Figure imgf000003_0001
The aminopyrazole intermediate 7 can be condensed with pyrazolo[l,5-a]pyrimidine-3- carboxylic acid a]pyrimidine-3-carboxylic acid (II) to afford 2-(4-amino-3-(5-chloro-2- (difluoromethoxy)phenyl)-lH-pyrazol-l-yl)-N,N-dimethylacetamide (III) and N-alkylated with N,N-dimethyl-bromoacetamide to afford I.
DETAILED DESCRIPTION OF THE INVENTION
The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
The phrase “a” or “an” entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms “a” (or “an”), “one or more”, and “at least one” can be used interchangeably herein.
As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or components, but may also include additional features or components. A bond drawn into ring system (as opposed to connected at a distinct vertex) indicates that the bond may be attached to any of the suitable ring atoms.
The term “optional” or “optionally” as used herein means that a subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example,
“optionally substituted” means that the optionally substituted moiety may incorporate a hydrogen or a substituent.
The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.
As used herein, the term “treating”, “contacting” or “reacting” when referring to a chemical reaction means to add or mix two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
An optionally substituted 2-hydroxyacetophenone refers to a compound which is optionally further substituted with one or two halogens, C1-3 alkyl, Ci-3-alkoxy, Ci-3-haloalkoxy moieties.
The term “alkyl” as used herein alone or in combination with other groups, denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms. The term “lower alkyl” denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms. "Ci-6 alkyl" as used herein refers to an alkyl composed of 1 to 6 carbons. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl, neope The term “haloalkyl” as used herein denotes an alkyl group as defined above wherein at least one hydrogen atom is substituted by a halogen. Examples are 1-fluorom ethyl, 1 -chi orom ethyl, 1-bromom ethyl, 1- iodom ethyl, difluorom ethyl, trifluoromethyl, tri chi orom ethyl, 1-fluoroethyl, 1-chloroethyl, 2- fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2- trifluoroethyl.
The term "alkoxy" as used herein means an -O-alkyl group, wherein alkyl is as defined above, such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, t- butyloxy, pentyloxy, hexyloxy, including their isomers. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "Ci-io alkoxy" as used herein refers to an-O-alkyl wherein alkyl is Ci-io.
The term "haloalkoxy" as used herein refers to a group -OR where R is haloalkyl as defined herein. The term "haloalkylthio" as used herein refers to a group -SR where R is haloalkyl as defined herein.
The term "halogen" or "halo" as used herein means fluorine, chlorine, bromine, or iodine.
The term “halo”, “halogen”, and “halide” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo.
Reduction of a nitro group to an amine can be accomplished with a metal reducing agent such as Fe, Sn or Zn, in a reaction inert solvent, e.g. MeOH, EtOH, EtOAc, benzene, toluene, xylene, o-dichlorobenzene, DCM, DCE, THF, dioxane, or mixtures thereof. If desired, when the reducing reagent is Fe, Sn or Zn, the reaction is carried out under acidic conditions in the presence of water. The reduction may be carried out by hydrogenation in the presence of a metal catalyst, e.g. nickel catalysts such as Raney nickel, palladium catalysts such as Pd/C, platinum catalysts such as PtCh, or ruthenium catalysts such as RuCh(Ph3P)3 under Eh atmosphere or in the presence of hydrogen sources such as hydrazine or formic acid. If desired, the reaction is carried out under acidic conditions, e.g, in the presence of HC1 or HOAc.
Carboxylic acids can be can be activated with agents such as EDC, DCC, benzotriazol-1 - yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), bromo-tris- pyrrolidinophosphonium hexafluorophosphate (PyBrOP), or 2-fluoro-l-methylpyridinium p- toluenesulphonate (Mukaiyama's reagent with or without a base such NMM, TEA or DIPEA in an inert solvent such as dimethylformamide (DMF) or di chi orom ethane at temperatures between 0 °C and 60 °C. Acylation of amines (J. March, supra pp.417-425; H. G. Benz, Synthesis of Amides and Related Compounds in Comprehensive Organic Synthesis, E. Winterfeldt, ed., vol. 6, Pergamon Press, Oxford 1991 pp. 381-411; see R. C. Larock, Comprehensive Organic Transformations A Guide to Functional Group Preparations , 1989, VCH Publishers Inc., New York; pp. 972-976) has been reviewed.
SCHEME 2
Figure imgf000006_0001
The laboratory scale preparation of I is depicted in Scheme 2 (P. Gibbons et al.,
WO2011/003065, p.43). Heretofore, the preparation of I was accomplished by protection of 4-nitro pyrazole (8a) with SEM-CI to afford 8b which was subjected to Pd(OAc)2 catalyzed coupling with 2-difluorom ethoxy-5 -chi oro bromobenzene to afford the amine 10 and condensed with 11 to afford the amide 12 which was subsequently deprotected. (Scheme 2)
SCHEME 3
Figure imgf000006_0002
The original process in Scheme 2 requires the protection and deprotection of the pyrazole nitrogen as a SEM ester that adds two steps to the process. In addition, the current process telescopes the conversion of 2 to 4 and the conversion of 4 to 6 minimizing the costs associated with the extra steps.
Commonly used abbreviations include: acetyl (Ac), aqueous (aq.), di(l-adamantyl)-n- butylphosphine ((Ad)2BuP), tert-butoxy carbonyl (Boc), di-tert-butyl pyrocarbonate or Boc anhydride (B0C20), benzyl (Bn), benzotriazol-l-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP), butyl (Bu), benzoyl (Bz), Chemical Abstracts Registration Number (CASRN), benzyloxycarbonyl (CBZ or Z), carbonyl diimidazole (CDI), N,N'- dicyclohexylcarbodiimide (DCC), 1,2-dichloroethane (DCE), di chi orom ethane (DCM), diethyl azodicarboxylate (DEAD), di-iso-propylazodi carboxyl ate (DIAD), iso- propylethylamine (DIPEA), N,N-dimethyl acetamide (DMA), 4-N,N-dimethylaminopyridine (DMAP), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1, l'-bis- (diphenylphosphino)ethane (dppe), l,r-bis-(diphenylphosphino)ferrocene (dppf), l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), ethyl (Et), ethyl acetate (EtOAc), ethanol (EtOH), diethyl ether (Et20), 0-(7-azabenzotriazole-l-yl)-N, N,N’N’- tetramethyluronium hexafluorophosphate acetic acid (HATU), acetic acid (HO Ac), 1-N- hydroxybenzotriazole (HOBt), (3-Hydroxy-3H-l,2,3-triazolo[4,5-b]pyridinato-0)tri-l- pyrrolidinyl-phosphorus hexafluorophosphate (PyAOP),high pressure liquid chromatography (HPLC), iso-propanol (IP A), methanol (MeOH), melting point (mp), MeS02- (mesyl or Ms), methyl (Me), acetonitrile (MeCN), mass spectrum (ms), methyl tert-butyl ether (MTBE), N- methylmorpholine (NMM), N-methylpyrrolidone (NMP), petroleum ether (pet ether, i.e. hydrocarbons), )phenyl (Ph), propyl (Pr), iso-propyl (z-Pr), pounds per square inch (psi), bromo-Zz/.s-pyrrolidinophosphonium hexafluorophosphate (PyBrOP), pyridine (pyr), room temperature (rt or RT), satd. (saturated), 2-(Trimethylsilyl)ethoxymethyl (SEM), tert- butyldimethylsilyl or t-BuMe2Si (TBDMS), triethylamine (TEA or Et3 ), triflate or CF3SO2- (Tf), trifluoroacetic acid (TFA), thin layer chromatography (TLC), tetrahydrofuran (THF), tetramethyl ethyl enediamine (TMEDA), trimethyl silyl or Me-, Si (TMS), 2- (trimethylsilyl)ethoxym ethyl (SEM), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), 4-Me-C6H4S02- or tosyl (Ts) Conventional nomenclature including the prefixes normal (n), iso (i-), secondary (sec-), tertiary (tert- or -t) and neo- have their customary meaning when used with an alkyl moiety. (J. Rigaudy and D. P. Klesney, Nomenclature in Organic Chemistry, IUPAC 1979 Pergamon Press, Oxford.).
COMPOUNDS AND PREPARATION Unless otherwise noted all reactions were run under a nitrogen atmosphere, solvents and reagents were used without further purification. 'H NMR (300 MHz, 500 MHz, 600 MHz), 13C NMR (125 MHz) were recorded on a Bruker Avance 3 spectrometer. Chemical shifts are reported in ppm (d units) downfield of internal tetramethylsilane [(CH3)4Si] or residual CHCh; coupling constants are reported in hertz (Hz). Multiplicities are as follows: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet. l-(5-chloro-2-(difluoromethoxy)phenvOethan-l-one
A reactor was charged with l-(5-chloro-2-hydroxyphenyl)ethan-l-one (2, 135 kg, 791 mol, 100 mol%), 2-propanol (541 kg), aqueous sodium hydroxide (539 kg, 4043 mol, 511 mol%, 30 wt%), and heated to 49 °C. Dichlorofluoromethane (248 kg, 2410 mol, 305 mol%) was bubbled into the reaction mixture and heated at 49 °C for >20 min until reaction was complete (<0.5 A% HPLC). The mixture was cooled to 20 °C and filtered. The cake was washed with 2-propanol (135 kg), and the combined filtrates charged back into the reactor. The reactor was heated to 27 °C for 15 min, let stand for 40 min without stirring to achieve phase separation and the aqueous phase was drained. The remaining organic phase was concentrated to ~ 200 L under reduced pressure at 45 °C, toluene (652 kg) was charged and heated to 27 °C for 40 min. The mixture was filtered and the cake washed with toluene (132 kg). The combined filtrates were recharged into the reactor followed by a rinse with toluene (50 kg). The reactor content was concentrated to -200 L under reduced pressure at 45 °C, toluene (268 kg) was charged and the solution of l-(5- chloro-2-
(difluoromethoxy)phenyl)ethan-l-one (3) in toluene was discharged to drums for subsequent use in the next step (83% corrected yield, 84.5 A% HPLC, 26.1% assay, KF = 0.1%, 2- propanol = 0.01%). sodium (Z)-3-(5-chloro-2-(difluoromethoxy)phenvD-3-oxoprop-l-en-l -olate (4)
A reactor was charged with ethyl formate (159.0 kg, 2146 mol, 328 mol%), a solution of 1- (5-chloro-2-(difluoromethoxy)phenyl)ethan-l-one (3) in toluene (144.5 kg assay corrected from the precursor step, 655 mol, 100 mol%), toluene (392 kg), ethyl formate (10.0 kg, 135 mol, 21 mol%), and heated to 41 °C. A solution of NaOEt in EtOH (360.0 kg, 952 mol, 145 mol%, 18 wt%) and toluene (16 kg) was charged and heated to 46 °C for 4 h. HPLC analysis showed 2 to be 2.1 A%. The reactor content was concentrated to -1100 L at <40 °C under reduced pressure, heptane (578 kg) was added and the mixture was concentrated to -800 L at <40 °C under reduced pressure, heptane (346 kg) was added again and the mixture concentrated to -800 L at <40 °C. This cycle was repeated 2 more times (using 346 kg of heptane each) followed by a last charge of heptane (340 kg). The reactor contents were then heated to 44 °C for 1 h, and cooled over 3 h to -3 °C, and stirred at this temperature for 2 h. The mixture was filtered, the cake washed with heptane (145 kg) and dried under vacuum for 24 h at 37 °C to give 196.4 kg of sodium (Z)-3-(5-chloro-2-(difluoromethoxy)phenyl)-3- oxoprop-l-en-l-olate (4, 76% corrected yield, 85.2 A% HPLC purity; 68.4% assay): mp = 181 °C; ¾ NMR (500 MHz, DMSO-d6) d 9.36 (d, J = 9.5 Hz, 1H), 8.50 (s, 1H), 8.43 (d, J =
10.1 Hz, 1H), 7.77 - 7.68 (m, 1H), 7.35 (dt, J = 8.7, 2.4 Hz, 2H), 7.14 (dd, J = 5.8, 3.0 Hz, 3H), 7.04 (s, 1H), 4.88 (d, J = 9.6 Hz, 1H), 4.82 (d, J = 10.2 Hz, 1H); 13C NMR (126 MHz, DMSO-d6) d 197.47, 185.61, 185.51, 166.97, 146.57, 146.54, 146.52, 139.80, 133.46,
133.07, 130.18, 129.77, 129.27, 128.11, 122.17, 121.94, 119.49, 117.44, 116.89, 105.64, 31.31. HRMS [M+H]+ calcd for CioHeCIFiNaCri 249.0125; found 249.0126.
3-(5-chloro-2-(difluoromethoxy)phenyl )-4-nitroso- l H-pyrazole)
A reactor was charged with formic acid (354 kg), acetonitrile (156 kg), water (44 kg) and cooled to -3 °C. Sodium (Z)-3-(5-chloro-2-(difluoromethoxy)phenyl)-3-oxoprop-l-en-l- olate (4) (67.0 kg assay corrected, 248 mol, 100 mol%) was added in one charge, and a solution of aqueous NaNC (110 kg, 303 mol, 122 mol%, 19 wt%) was dosed into the solution over 1 h, followed by a rinse with water (4 kg), and stirred for 3 h. HPLC analysis showed 4 was undetected. The reactor was heated to 2 °C, aqueous hydrazine monohydrate (102 kg, 326 mol, 131 mol%, 16 wt%) was added over 1 h and stirred for 3 h at 6 °C. HPLC analysis showed 5 to be 1.0 A%. The reactor was charged with toluene (57 kg), followed by water (468 kg) over 1 h, and cooled to - 7 °C for 4 h. The mixture was filtered, the cake washed with water (248 kg) and dried under vacuum at 33 °C for 33 h to give 42.7 kg of 3- (5-chloro-2-(difluoromethoxy)phenyl)-4-nitroso-lH-pyrazole (6) as a green solid (61% yield,
97.2 A% HPLC, 96.0% assay): mp = 149 °C; ¾ NMR (500 MHz, DMSO-d6) d 7.81 (s, 1H), 7.72 (dd, J = 8.8, 2.7 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.17 (s, 1H), 7.02 (s, 1H); 13C NMR (126 MHz, DMSO-d6) d 161.74, 148.77, 132.26, 131.44, 129.61, 120.67, 118.78, 116.72, 114.66.
¾ NMR (500 MHz, DMSO-de) d 7.81 (s, 1H), 7.72 (dd, J = 8.8, 2.7 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.17 (s, 1H), 7.02 (s, 1H); 13C NMR (126 MHz, DMSO- ) d 161.74, 148.77, 132.26, 131.44, 129.61, 120.67, 118.78, 116.72, 114.66. HRMS [M+H]+ calcd for C10H6CIF2N3O2274.0190; found 274.0194. 3-(5-chloro-2-(difluoromethoxy)phenvO-lH-pyrazol -4-amine hydrochloride
A reactor was charged with NaBH4 (92.9 kg, 2455 mol, 1681 mol%), CuCl (1.10 kg, 11 mol, 69 mol%), THF (440 kg) and heated to 26 °C. A solution of 6 (41.6 kg, 146 mol, 100 mol%) in EtOH (360 kg) was added over 15 h, followed by two rinses with EtOH (50 kg, 48 kg), and continued to stir for 24 h. HPLC analysis showed 6 to be 0.5 A%. A solution of HC1 gas in EtOH (653 kg, 4966 mol, 3400 mol%, 6 M) was added over 16 h and stirred at 22 °C for 3 h. Diatomaceous earth (86.2 kg, diatomite) and EtOH (11 kg) was added and stirred for 2 h at 26 °C . The mixture was filtered and the cake washed with five portions of EtOH (256 kg each). The combined filtrate was charged to a reactor and concentrated to -270 L at < 45 °C under reduced pressure. The reactor was cooled to 26 °C, charged with MeOH (600 kg) and concentrated to -230 L at < 45 °C under reduced pressure. The reactor was cooled to 26 °C, charged with MeOH (486 kg) and concentrated to -230 L at < 45 °C under reduced pressure. The reactor was cooled to 26 °C, charged with MeOH (102 kg), title compound seeds and concentrated to -230 L at < 45 °C under reduced pressure. The reactor was cooled to 26 °C, charged with MTBE (700 kg) and cooled over 4 h to 2 °C and held at this temperature for 8 h. The mixture was filtered, the cake washed three times with MTBE (235 kg each) and dried under vacuum at 70 °C for 44 h to give 72.2 kg of 3-(5-chloro-2-(difluoromethoxy)phenyl)- lH-pyrazol-4-amine hydrochloride (7, 72% yield, 99.9 A% HPLC, 97.7% assay) as a yellow solid: mp = 181 °C; ¾ NMR (500 MHz, DMSO-d6) d 13.52 (s, 1H), 10.00 (s, 3H), 7.95 (s, 1H), 7.71 (d, J = 2.7 Hz, 1H), 7.61 (dd, J = 8.8, 2.7 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.17 (s, 1H); 13C NMR (126 MHz, DMSO-d6) d 147.52, 131.20, 129.95, 121.67, 118.71, 116.64,
114.56, 112.52; HRMS calcd for CioHsCIFiNsO 260.0397; found m/z 260.0396.
The features disclosed in the foregoing description, or the following claims, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilized for realizing the invention in diverse forms thereof.
The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.
The patents, published applications, and scientific literature referred to herein establish the knowledge of those skilled in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually.
# # # # # # # #

Claims

We claim:
1. A process for the preparation of 3-(5-chloro-2-(difluoromethoxy)phenyl)-lH-pyrazol-4- amine (6) which process comprises the steps of:
(i) treating an optionally substituted 2-hydroxy-acetophenone with chlorodifluoromethane to afford the difluoromethyl ether 3
Figure imgf000012_0001
(ii) 3, without purification, is treated with formic acid ester and base to afford the enolate
4
Figure imgf000012_0002
(iii) treating the enolate in situ with a nitrosating agent sodium nitrite to afford the nitroso compound 5
Figure imgf000012_0003
(iv) treating the nitroso-P-di carbonyl 5, without further purification, with hydrazine to afford a nitroso-pyrazole 6
Figure imgf000013_0001
(v) and, reducing the a nitroso group to afford the aminopyrazole and optionally converting the amine to a salt with an organic acid
Figure imgf000013_0002
2. The process of claim 1 wherein the optionally substituted 2-hydroxyacetophenone is 2- hydroxy-5-chloro-acetophenone, the reducing agent is NaBTB/CuCl and the formate ester, the base is ethyl formate and sodium ethoxide, the nitrosating agent is sodium nitrite.
PCT/US2022/031685 2021-06-03 2022-06-01 Process for preparing medicaments WO2022256358A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163196382P 2021-06-03 2021-06-03
US63/196,382 2021-06-03

Publications (1)

Publication Number Publication Date
WO2022256358A1 true WO2022256358A1 (en) 2022-12-08

Family

ID=82321522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/031685 WO2022256358A1 (en) 2021-06-03 2022-06-01 Process for preparing medicaments

Country Status (1)

Country Link
WO (1) WO2022256358A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003065A2 (en) 2009-07-02 2011-01-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2015177326A1 (en) 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
WO2018166993A2 (en) * 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003065A2 (en) 2009-07-02 2011-01-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2015177326A1 (en) 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
WO2018166993A2 (en) * 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E. HANAN ET AL., J. MED. CHEM., vol. 55, 2012, pages 10090 - 10107
H. G. BENZ: "Comprehensive Organic Transformations - A Guide to Functional Group Preparations", 1989, VCH PUBLISHERS INC., pages: 972 - 976
J. RIGAUDYD. P. KLESNEY: "Nomenclature in Organic Chemistry, IUPAC", 1979, PERGAMON PRESS

Similar Documents

Publication Publication Date Title
JP5934742B2 (en) Process for the production of pharmaceutically active compounds
CA2847728C (en) Processes and intermediates for making a jak inhibitor
CA3210320A1 (en) Synthesis of a bruton&#39;s tyrosine kinase inhibitor
EP3215507B1 (en) Synthesis of copanlisib and its dihydrochloride salt
TW201625634A (en) Synthesis of COPANLISIB and its dihydrochloride salt
CA2786402A1 (en) Pyrrolopyrazine derivatives and their use as jak and syk inhibitors
JP2023544678A (en) Substituted tricyclic compounds
KR102396059B1 (en) Novel compound and method for preparing same
CA3058682A1 (en) Processes for the preparation of acalabrutinib and intermediates thereof
WO2022256358A1 (en) Process for preparing medicaments
Shaabani et al. A novel strategy of Ugi-4CR/huisgen 1, 3-Dipolar synthesis of 1H-1, 2, 3-triazole-modified peptidoimetics
TWI812679B (en) Process for preparing soluble guanylate cyclase stimulators
TW201625632A (en) Synthesis of PI3K inhibitor and salts thereof
WO2010049500A2 (en) A process for the preparation of tadalafil.
TWI389912B (en) Process for the preparation of n-[5-(3-dimethylamino-acryloyl)-2-fluoro-phenyl]-n-methyl-acetamide
TWI809489B (en) Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamide
Verma et al. Synthesis of new 2, 3-disubstituted pyridines containing a 1, 2, 3-triazole in the side-chain via one-pot copper-catalyzed azide-alkyne cycloaddition
CN110759923B (en) Pyrimidopyrrolopyridazine derivatives, intermediates thereof, preparation method, pharmaceutical compositions and uses
CN115215921A (en) Preparation method of connection base drug conjugate and intermediate thereof
CN115385926A (en) Preparation method of connection base drug conjugate and intermediate thereof
WO2003024964A1 (en) Tricyclic pyridin-2-one analogues as gaba-a receptor ligands
CN111410650A (en) Process for the preparation of sulfonamides
JPH04279571A (en) Production of aromatic condensed imidazole compound
NZ616395B2 (en) Androgen receptor modulating carboxamides for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22735714

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22735714

Country of ref document: EP

Kind code of ref document: A1